CMS’ Brooks-LaSure: Early Action Impacting Pharma Likely To Focus On Legacy Trump Policies
Chiquita Brooks-LaSure’s nomination was approved in a 55-44 vote, with five Republicans joining Democrats in favor. Her confirmation clears the way for other appointments to key positions at the agency, such as the directors of the centers for Medicare and Medicaid.
You may also be interested in...
US FDA’s apolitical leadership team is highly unusual – but is it a strength or a weakness in a new Administration? Acting Commissioner Janet Woodcock has been running the agency for nearly six months and there are no signs of the status quo changing any time soon.
After months of reticence about his Administration's plans for tackling drug pricing, Biden's executive order offers some clues about what might be in store and what kind of timeline they are working with.
CMS’s Innovation director Elizabeth Fowler wants to ‘reignite’ momentum behind health care system transformation. What does that mean for biopharma?